Next-generation drug discovery for neurodegenerative diseasesvergegenomics.com
We started Verge with the vision of building a therapeutics company that takes a patient-data driven approach to unlock a spectrum of therapies that have escaped traditional drug discovery, beginning with diseases where patients need solutions the most: neurodegenerative disease.
Verge is developing therapies for neurological diseases with a unique all-in-human platform. Advances in data from patients are rapidly promoting the understanding of the biology of diseases of the central nervous system, allowing for the identification of disease targets. Verge de-risks these targets in patient-derived neurons in the laboratory to generate small molecules, creating a pipeline of potential therapeutics in early development for many diseases, including ALS and Parkinson's.